Pemphigus Vulgaris Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies – Ixaka Ltd (formerly Rexgenero), Hemostemix Inc Lisata Therapeutics/ Caladr

DelveInsight Business Research LLP

Pemphigus Vulgaris Overview

Pemphigus Vulgaris is a common manifestation of arterial stenosis of the lower and/or upper extremities that reduces arterial flow. It is well known that Pemphigus Vulgaris is associated with elevated morbidity and mortality with cardiovascular disease. In Pemphigus Vulgaris, the legs or arms, usually the legs, do not receive enough blood flow to keep up with the demand, which may cause leg pain when walking (claudication) and other symptoms. Many people with Pemphigus Vulgaris have no symptoms. The most common symptom of lower-extremity Pemphigus Vulgaris is painful muscle cramping in the hips, thighs, or calves when walking, climbing stairs, or exercising. However, those who develop a painful ache in their legs when they walk usually disappear after a few minutes of rest. The medical term for this is “intermittent claudication”. The symptoms of Pemphigus Vulgaris often develop slowly over time. If your symptoms develop quickly or get suddenly worse, it could be a sign of a serious problem requiring immediate treatment.

Pemphigus Vulgaris Epidemiology Insights

• In 2022, the market size of Pemphigus Vulgaris was highest in the US among the 7MM accounting for approximately USD 4 billion, and lowest in Spain with USD 130 million which is further expected to increase by 2032.

• Gender-specific diagnosed prevalent cases of Pemphigus Vulgaris  were higher in females (9 million cases) as compared to males (8 million) in 2022 in the 7MM.

• According to DelveInsight estimates, the US accounted for approximately 9 million cases, which was the highest diagnosed prevalent cases of Pemphigus Vulgaris , followed by EU4 and the UK with 5 million cases, and Japan with 2 million cases in 2022. These cases are expected to increase in the US, EU4, the UK, and Japan by 2032

• Among the European countries, Germany had the highest diagnosed prevalent population of Pemphigus Vulgaris  (approximately 2 million cases), followed by Italy (approximately 1 million cases) in 2022. On the other hand, Spain (0.7 million cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

• Pemphigus Vulgaris has been identified as a male-dominant disease; however, in our analysis, the number of women suffering was higher than males. In 2022, 49% of cases of Pemphigus Vulgaris were in males, while 51% of cases were in Females in the 7MM.

Click here to learn more about the Pemphigus Vulgaris Market Landscape

The Report Covers the Pemphigus Vulgaris Epidemiology Segmented by:

• Total Pemphigus Vulgaris prevalent cases 

• Total Pemphigus Vulgaris type-specific prevalent cases 

• Total Pemphigus Vulgaris diagnosed cases 

• Total Pemphigus Vulgaris treatable cases 

Pemphigus Vulgaris Market Outlook 

The overall medical treatment for Pemphigus Vulgaris is comprehensive and involves lowering cholesterol, antiplatelet therapy, anticoagulation, peripheral vasodilators, blood pressure control, exercise therapy, and quitting smoking. Numerous medications are available for managing claudication symptoms, secondary prevention of cardiovascular problems, and limb salvage therapy. Lifestyle change, medication management, endovascular therapies, and surgical interventions are different treatment options. Following this regime can lessen atherosclerosis-related systemic problems like stroke, myocardial infarction, and limb-related complications, including critical limb ischemia and amputation. Pemphigus Vulgaris  is undertreated compared to coronary artery disease. The current treatment strategies include endovascular revascularization, surgical revascularization, and primary amputation, and endovascular revascularization is a fundamental strategy to limb preservation. Other than surgical approaches, therapeutic angiogenesis can be achieved by gene and cell therapy. Collategene (HGF plasmid) is the only gene therapy that received approval in Japan. Apart from this, many cell therapies are under development.

Key Companies Working in the Pemphigus Vulgaris Market

• Ixaka Ltd (formerly Rexgenero)

• Hemostemix Inc

• Lisata Therapeutics/ Caladrius Biosciences

• Reven Pharmaceuticals, Inc

• Helixmith Co., Ltd

And many others 

Pemphigus Vulgaris Therapies Covered and Analyzed in the Report

• ACP-01

• Rivaroxaban 

• Ticagrelor

• Clopidogrel

• Vonapanitase

And many others 

Learn more about the Key Companies and Emerging Therapies in the Pemphigus Vulgaris  Market

Table of Contents 

1. Key Insights 

2. Pemphigus Vulgaris Introduction 

3. Executive Summary of Pemphigus Vulgaris             

4. Disease Background and Overview

5. Epidemiology and patient population

6. Pemphigus Vulgaris Emerging Therapies

7. Pemphigus Vulgaris Market Outlook

8. Pemphigus Vulgaris Market Access and Reimbursement of Therapies

9. Pemphigus Vulgaris  Market Drivers 

10. Pemphigus Vulgaris Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Pemphigus Vulgaris Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services